BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 24429550)

  • 1. Pulmonary lymphangiectasia resulting from vascular endothelial growth factor-C overexpression during a critical period.
    Yao LC; Testini C; Tvorogov D; Anisimov A; Vargas SO; Baluk P; Pytowski B; Claesson-Welsh L; Alitalo K; McDonald DM
    Circ Res; 2014 Feb; 114(5):806-22. PubMed ID: 24429550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues.
    Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K
    Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperplasia, de novo lymphangiogenesis, and lymphatic regression in mice with tissue-specific, inducible overexpression of murine VEGF-D.
    Lammoglia GM; Van Zandt CE; Galvan DX; Orozco JL; Dellinger MT; Rutkowski JM
    Am J Physiol Heart Circ Physiol; 2016 Aug; 311(2):H384-94. PubMed ID: 27342876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
    Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
    Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anatomy and function of the lymphatic vessels in the parietal pleura and their plasticity under inflammation in mice.
    Ren Y; Okazaki T; Ngamsnae P; Hashimoto H; Ikeda R; Honkura Y; Suzuki J; Izumi SI
    Microvasc Res; 2023 Jul; 148():104546. PubMed ID: 37230165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
    Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
    Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital Pulmonary Lymphangiectasia: A Disorder not only of Fetoneonates.
    Yuan SM
    Klin Padiatr; 2017 Jul; 229(4):205-208. PubMed ID: 28718185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.
    Karpanen T; Wirzenius M; Mäkinen T; Veikkola T; Haisma HJ; Achen MG; Stacker SA; Pytowski B; Ylä-Herttuala S; Alitalo K
    Am J Pathol; 2006 Aug; 169(2):708-18. PubMed ID: 16877368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.
    Baluk P; Tammela T; Ator E; Lyubynska N; Achen MG; Hicklin DJ; Jeltsch M; Petrova TV; Pytowski B; Stacker SA; Ylä-Herttuala S; Jackson DG; Alitalo K; McDonald DM
    J Clin Invest; 2005 Feb; 115(2):247-57. PubMed ID: 15668734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential lymphatic growth in bronchus-associated lymphoid tissue in sustained lung inflammation.
    Baluk P; Adams A; Phillips K; Feng J; Hong YK; Brown MB; McDonald DM
    Am J Pathol; 2014 May; 184(5):1577-92. PubMed ID: 24631179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis.
    Durré T; Morfoisse F; Erpicum C; Ebroin M; Blacher S; García-Caballero M; Deroanne C; Louis T; Balsat C; Van de Velde M; Kaijalainen S; Kridelka F; Engelholm L; Struman I; Alitalo K; Behrendt N; Paupert J; Noel A
    Nat Commun; 2018 Dec; 9(1):5178. PubMed ID: 30518756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis.
    Jones D; Xu Z; Zhang H; He Y; Kluger MS; Chen H; Min W
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2553-61. PubMed ID: 20864667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of VEGFR-3 and 5'-nase in regenerating lymphatic vessels of the cutaneous wound healing.
    Ji RC; Miura M; Qu P; Kato S
    Microsc Res Tech; 2004 Jun; 64(3):279-86. PubMed ID: 15452895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient activation of the lymphangiogenic growth factor VEGF-C requires the C-terminal domain of VEGF-C and the N-terminal domain of CCBE1.
    Jha SK; Rauniyar K; Karpanen T; Leppänen VM; Brouillard P; Vikkula M; Alitalo K; Jeltsch M
    Sci Rep; 2017 Jul; 7(1):4916. PubMed ID: 28687807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.